2 September 2019 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that Robin Carr, a renowned industry veteran who has worked at GSK and Astex, is to head up and form a C4XD Drug Discovery Advisory Network.
At least one biotechnology company that develops new drugs for a living has created its own virtual reality platform for drug discovery. Founded in 2007, C4X Discovery (C4XD) out of Manchester, England, is a small-cap public company that has developed its own VR platform called 4Sight.
Dr Craig Fox, Chief Scientific Officer of C4X Discovery #C4XD discusses their collaboration with PhoreMost to accelerate Parkinson's Disease drug discovery pipeline.
(Interview starts at 10 minutes 15 seconds)
Chemists at C4X Discovery are using the virtual reality technology behind popular game Fortnite to visualize the structure of complex molecules. The tool, called 4Sight, has already been used to create a drug that is now in development to treat addiction.
25 June 2019 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today entered into a collaboration with PhoreMost, a UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets. The collaboration, focused initially in Parkinson’s Disease, will combine both company’s technology platforms.
For U.K.-based C4X Discovery Holdings PLC, gaming engines are powering a more efficient drug-discovery process. The company uses the engines to discover molecules that help fight diseases like Alzheimer’s, Parkinson’s and ulcerative colitis, then licenses the resulting drugs to customers.
30 April 2019 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces its interim results for the six months ended 31 January 2019.
17 December 2018 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that it has entered into an exclusive target discovery partnership with Horizon Discovery Group plc (“Horizon”, AIM: HZD), a global leader in the application of gene editing and gene modulation technologies. The partnership aims to validate novel synthetic lethal oncology targets that have been identified by Horizon’s cutting-edge CRISPR-Cas9 technology leading to the generation of potential new drugs for patients with limited effective treatments such as colorectal and lung cancer.